Song Z, Huang Q, Xu S, Zhou J, Zhang C
Ther Innov Regul Sci. 2024; 58(4):773-787.
PMID: 38683419
DOI: 10.1007/s43441-024-00633-6.
Singh P, Hernandez-Rauda R, Pena-Rodas O
Food Sci Nutr. 2023; 11(6):2547-2579.
PMID: 37324885
PMC: 10261805.
DOI: 10.1002/fsn3.3314.
Nassar M, Abosheaishaa H, Singh A, Misra A, Bloomgarden Z
J Diabetes. 2023; 15(2):86-96.
PMID: 36690377
PMC: 9934962.
DOI: 10.1111/1753-0407.13359.
Lin S, Yang Z
Proc Natl Acad Sci U S A. 2023; 120(3):e2220329120.
PMID: 36623179
PMC: 9933086.
DOI: 10.1073/pnas.2220329120.
Narayanan N, Naik D, Sahoo J, Kamalanathan S
World J Virol. 2022; 11(6):399-410.
PMID: 36483108
PMC: 9724202.
DOI: 10.5501/wjv.v11.i6.399.
The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus.
Sadidi M, Zare A, Nasrollahzadehsabet M, Dastan F, Mosadegh Khah A, Jafari Asheyani M
J Res Med Sci. 2022; 27:62.
PMID: 36353337
PMC: 9639723.
DOI: 10.4103/jrms.jrms_71_22.
Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?.
Alomair B, Al-Kuraishy H, Al-Buhadily A, Al-Gareeb A, De Waard M, Elekhnawy E
Inflammopharmacology. 2022; 30(6):2411-2415.
PMID: 36180664
PMC: 9524728.
DOI: 10.1007/s10787-022-01078-9.
Novel hit of DPP-4Is as promising antihyperglycemic agents with dual antioxidant/anti-inflammatory effects for type 2 diabetes with/without COVID-19.
Mahgoub S, Fatahala S, Sayed A, Atya H, El-Shehry M, Afifi H
Bioorg Chem. 2022; 128:106092.
PMID: 35985159
PMC: 9364673.
DOI: 10.1016/j.bioorg.2022.106092.
Plasma metabolome and cytokine profile reveal glycylproline modulating antibody fading in convalescent COVID-19 patients.
Yang Z, Wu D, Lu S, Qiu Y, Hua Z, Tan F
Proc Natl Acad Sci U S A. 2022; 119(34):e2117089119.
PMID: 35943976
PMC: 9407385.
DOI: 10.1073/pnas.2117089119.
The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis.
Chen Y, Lv X, Lin S, Arshad M, Dai M
Front Endocrinol (Lausanne). 2022; 13:895458.
PMID: 35692410
PMC: 9186017.
DOI: 10.3389/fendo.2022.895458.
Going viral in the islet: mediators of SARS-CoV-2 entry beyond ACE2.
Rangu R, Wander P, Barrow B, Zraika S
J Mol Endocrinol. 2022; 69(2):R63-R79.
PMID: 35521990
PMC: 10622140.
DOI: 10.1530/JME-21-0282.
Impact of diabetes on COVID-19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta-analysis.
Kastora S, Patel M, Carter B, Delibegovic M, Myint P
Endocrinol Diabetes Metab. 2022; 5(3):e00338.
PMID: 35441801
PMC: 9094465.
DOI: 10.1002/edm2.338.
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis.
Nguyen N, Ho D, Nguyen H, Ho D, Li H, Lin C
Metabolism. 2022; 131:155196.
PMID: 35367460
PMC: 8970613.
DOI: 10.1016/j.metabol.2022.155196.
Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants including Omicron (B.1.1.529).
Yonekawa A, Shimono N
Biology (Basel). 2022; 11(3).
PMID: 35336774
PMC: 8945151.
DOI: 10.3390/biology11030400.
Impact of diabetes and Krebs von den Lungen-6 on coronavirus disease 2019 severity: A single-center study from Japan.
Yakushiji Y, Motoyama K, Fukuda M, Takahashi H, Kimura M, Tazoe S
J Diabetes Investig. 2022; 13(7):1277-1285.
PMID: 35243802
PMC: 9114902.
DOI: 10.1111/jdi.13784.
Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients.
Nadasdi A, Sinkovits G, Bobek I, Lakatos B, Forhecz Z, Prohaszka Z
Biomark Med. 2022; 16(5):317-330.
PMID: 35195023
PMC: 8961475.
DOI: 10.2217/bmm-2021-0717.
The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence.
Zhang T, Tong X, Zhang S, Wang D, Wang L, Wang Q
Front Pharmacol. 2021; 12:731453.
PMID: 34955820
PMC: 8696080.
DOI: 10.3389/fphar.2021.731453.
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 - A systematic review and meta-analysis.
Zein A, Raffaello W
Prim Care Diabetes. 2021; 16(1):162-167.
PMID: 34952805
PMC: 8666291.
DOI: 10.1016/j.pcd.2021.12.008.
Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review.
Popovic D, Papanas N, Pantea Stoian A, Rizvi A, Janez A, Rizzo M
Diabetes Ther. 2021; 12(12):3037-3054.
PMID: 34699021
PMC: 8546380.
DOI: 10.1007/s13300-021-01170-3.
Old Problem, New Concerns: Hypercortisolemia in the Time of COVID-19.
Berlinska A, Swiatkowska-Stodulska R, Sworczak K
Front Endocrinol (Lausanne). 2021; 12:711612.
PMID: 34675878
PMC: 8524078.
DOI: 10.3389/fendo.2021.711612.
